Calamos Advisors’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$26.6M Buy
75,496
+5,748
+8% +$2.05M 0.09% 228
2025
Q4
$22.8M Sell
69,748
-2,821
-4% -$895K 0.09% 241
2025
Q3
$20.5M Buy
72,569
+244
+0.3% +$70.8K 0.08% 273
2025
Q2
$20.2M Hold
72,325
0.08% 266
2025
Q1
$22.5M Buy
72,325
+840
+1% +$248K 0.1% 234
2024
Q4
$18.6M Hold
71,485
0.08% 271
2024
Q3
$23M Sell
71,485
-1,814
-2% -$593K 0.1% 238
2024
Q2
$22.9M Sell
73,299
-2,673
-4% -$785K 0.1% 230
2024
Q1
$21.6M Sell
75,972
-1,909
-2% -$559K 0.1% 238
2023
Q4
$22.4M Sell
77,881
-1,016
-1% -$277K 0.11% 231
2023
Q3
$21.2M Sell
78,897
-32
-0% -$7.99K 0.11% 228
2023
Q2
$17.5M Sell
78,929
-48
-0.1% -$11.1K 0.09% 283
2023
Q1
$19.1M Sell
78,977
-9,862
-11% -$2.42M 0.09% 269
2022
Q4
$23.3M Sell
88,839
-15,682
-15% -$4.2M 0.11% 239
2022
Q3
$23.6M Hold
104,521
0.11% 225
2022
Q2
$25.4M Buy
104,521
+2,903
+3% +$711K 0.11% 220
2022
Q1
$24.6M Buy
101,618
+13,589
+15% +$3.12M 0.09% 248
2021
Q4
$19.8M Buy
88,029
+3,408
+4% +$719K 0.07% 280
2021
Q3
$18M Buy
84,621
+7,467
+10% +$1.72M 0.08% 272
2021
Q2
$18.8M Buy
77,154
+17,549
+29% +$4.32M 0.09% 263
2021
Q1
$14.8M Buy
59,605
+1,842
+3% +$440K 0.08% 265
2020
Q4
$13.3M Sell
57,763
-47,158
-45% -$10.9M 0.08% 274
2020
Q3
$26.7M Sell
104,921
-5,289
-5% -$1.31M 0.17% 151
2020
Q2
$26M Sell
110,210
-4,270
-4% -$974K 0.18% 150
2020
Q1
$23.2M Sell
114,480
-44,917
-28% -$9.81M 0.18% 163
2019
Q4
$38.4M Sell
159,397
-1,241
-0.8% -$274K 0.19% 149
2019
Q3
$31.1M Buy
160,638
+90,392
+129% +$17.4M 0.17% 173
2019
Q2
$12.9M Buy
70,246
+9,777
+16% +$1.75M 0.07% 297
2019
Q1
$11.5M Sell
60,469
-436
-0.7% -$83.3K 0.07% 290
2018
Q4
$11.9M Sell
60,905
-41,681
-41% -$8.13M 0.08% 276
2018
Q3
$21.3M Sell
102,586
-21,772
-18% -$4.29M 0.12% 214
2018
Q2
$23M Sell
124,358
-16,606
-12% -$2.94M 0.14% 199
2018
Q1
$24M Sell
140,964
-61,186
-30% -$11.2M 0.16% 188
2017
Q4
$35.2M Sell
202,150
-11,860
-6% -$2.1M 0.18% 121
2017
Q3
$39.9M Sell
214,010
-15,801
-7% -$2.8M 0.31% 96
2017
Q2
$39.6M Buy
229,811
+138,852
+153% +$22.6M 0.29% 93
2017
Q1
$14.9M Sell
90,959
-183
-0.2% -$30.4K 0.12% 229
2016
Q4
$13.3M Sell
91,142
-4,324
-5% -$651K 0.11% 226
2016
Q3
$15.9M Buy
95,466
+79
+0.1% +$13.4K 0.11% 218
2016
Q2
$14.5M Buy
95,387
+30
+0% +$4.66K 0.1% 232
2016
Q1
$14.3M Buy
95,357
+5,049
+6% +$750K 0.09% 228
2015
Q4
$14.7M Buy
90,308
+1,400
+2% +$220K 0.09% 232
2015
Q3
$12.3M Buy
88,908
+26
+0% +$4.1K 0.08% 242
2015
Q2
$13.6M Sell
88,882
-4,281
-5% -$686K 0.08% 235
2015
Q1
$14.9M Buy
93,163
+47
+0.1% +$7.4K 0.09% 221
2014
Q4
$14.8M Buy
93,116
+416
+0.4% +$64.8K 0.1% 219
2014
Q3
$13M Hold
92,700
0.09% 225
2014
Q2
$11M Buy
92,700
+30,700
+50% +$3.55M 0.07% 244
2014
Q1
$7.65M Hold
62,000
0.05% 269
2013
Q4
$7.08M Hold
62,000
0.05% 278
2013
Q3
$6.94M Sell
62,000
-485,175
-89% -$52.6M 0.04% 269
2013
Q2
$54M Buy
+547,175
New +$56.8M 0.35% 76

Other funds holding AMGN

Calamos Advisors's AMGN Position: Q1 2026 in Review

Calamos Advisors increased its Amgen (AMGN) stake by 8.2% in Q1 2026, buying an estimated $2.05M and bringing the position to 75,496 shares worth $26.6M. The position accounts for 0.09% of the portfolio, ranked #228.

Calamos Advisors first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $54M in Q2 2013. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Calamos Advisors held 75,496 shares of Amgen worth $26.6M as of Q1 2026.
  • Calamos Advisors bought 5,748 Amgen shares in Q1 2026, an estimated $2.05M.
  • Amgen made up 0.09% of Calamos Advisors's portfolio in Q1 2026, its #228 holding.
  • Calamos Advisors first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
  • Calamos Advisors's Amgen position peaked at $54M in Q2 2013.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.